Cotrimoxazole preventive therapy in adults and pregnant women with HIV: a systematic review and meta-analysis
|
|
- Randolph McGee
- 5 years ago
- Views:
Transcription
1 Cotrimoxazole preventive therapy in adults and pregnant women with HIV: a systematic review and meta-analysis
2 Introduction Global efforts to scale-up antiretroviral therapy (ART) averted an estimated 4.2 million deaths in low- and middle-income countries from [1]. All United Nations member states endorsed this important impact and agreed to continue scale-up of ART to 15 million people by 2015 [2]. In 2012, 9.7 million (65% of the United Nations target) were receiving ART [1]. While limited access to ART contributed to the 1.6 million deaths among the 35.3 million people with HIV in 2012, concomitant infections are also an important cause of death [3]. Cotrimoxazole is a fixed-dose combination of two antimicrobial agents (sulfamethoxazole and trimethoprim) that prevents a wide spectrum of infections among people with HIV. WHO recommends cotrimoxazole preventive therapy in HIV-infected adults and pregnant women with CD4 counts below 350 cells/µl [4]. Discontinuation can be considered in individuals with CD4 counts above 350 cells/µl after at least six months of ART. Despite policies for cotrimoxazole preventive therapy in most countries, nationwide implementation remains problematic [5]. The reasons for the incomplete implementation of national policies are various and include service, patient, and demographic barriers. For example, in Malawi nationwide implementation only occurred after (1) completion of local cotrimoxazole operational research, (2) nationwide dissemination of findings through the Ministry of Health, (3) changes in national policy, and (4) the development of monitoring tools, drug procurement and distribution, and training packages [6]. Previous systematic reviews have reviewed Pneumocystis jirovecii pneumonia (PCP) prophylaxis among people not receiving ART [7-9], discontinuation of PCP prophylaxis after ART-induced CD4 recovery [10], cotrimoxazole initiation in people not receiving ART with advanced disease [11], cotrimoxazole initiation in people receiving ART with advanced disease [12], and PCP prophylaxis dosing [8]. Given these reviews only included a few studies conducted in low- and middle-income countries, The objective of this article is to systematically review cotrimoxazole initiation, discontinuation, and dosing in adults and pregnant women with HIV globally. Methods Conduct of systematic review
3 This systematic review will be conducted in accordance with PRISMA guidelines [13]. The PubMed, Embase, African Index Medicus, Index Medicus for the Eastern Mediterranean Region, Index Medicus for the Southeast Asia Region, Western Pacific Region Index Medicus, and Latin American and Caribbean Health Science Literature databases will be systematically searched without language, publication, date, or any other limits. The WHO International Clinical Trials Registry Platform, the Cochrane Central Register of Controlled Trials, the International Standard Randomised Controlled Trial Number Register, and ClinicalTrials.gov will be searched for future and on-going studies. Experts in the field will be contacted to identify unpublished research and on-going studies. Search strategy and selection criteria The search strategies (Table 1) were designed to identify studies including people with HIV using cotrimoxazole. Per recommendations from the PRISMA Group, eligibility criteria were based on key study characteristics: population, intervention, comparator, outcome, and design [13]. For issues related to initiation or discontinuation of cotrimoxazole, studies will be included when (1) the study population included adults, pregnant women, or breastfeeding women with HIV, (2) the intervention was daily cotrimoxazole, (3) the comparator was no cotrimoxazole (except in settings with moderate-high malaria transmission, where pregnant women ineligible for cotrimoxazole should receive intermittent preventive treatment [14]), (4) the outcomes were death, new WHO clinical stage 3 or 4 event, diarrhoea, pneumonia, malaria, severe bacterial infections, tuberculosis, treatment limiting adverse event, hospitalisation rates, cost or cost-effectiveness, acceptability, retention in care, or adherence to ART, and (5) the study design was a randomised trial or observational cohort study. For cotrimoxazole dosing, the study population will remain the same, the intervention will be 480 mg of cotrimoxazole daily, the comparator will be 960 mg of cotrimoxazole daily, and the outcomes and study designs will remain the same. Two investigators will independently screen abstracts of all identified articles and then match the full texts of all articles selected during screening against the inclusion criteria. Articles meeting the inclusion criteria will be included in this review. Data extraction Two investigators will complete the data extraction using a standardised extraction spreadsheet comprising four tables. The first table will summarise the characteristics of study
4 participants. The second table will summarise study methods. The third table will summarise the reported outcomes. The final table will focus on quality assessment. Statistical analyses Studies meeting eligibility criteria will be stratified by (1) pregnancy/breastfeeding status, (2) clinical stage or level of immunodeficiency, and/or (3) viral suppression. If there are an adequate number of studies meeting eligibility criteria for key analyses, a funnel plot with the effect measures on the x-axis and standard error of the log for the effect measures on the y- axis will be created to assess publication bias and the Egger and Begg tests will be used to test the funnel plot s symmetry. If studies are similar enough to combine after stratification, meta-analyses will be performed and statistical heterogeneity will be assessed. Effect measures will be entered as the natural log of the effect measure and standard error as the natural log of (95% upper limit 95% lower limit) 3.92 [15]. Since it is possible that the magnitude and direction of cotrimoxazole s impact could differ for reasons other than chance, random-effects models will be used for all analyses. For non-inferiority and equivalency analyses, a 10% margin will be used to compare the risk of outcomes [16, 17]. An I-squared statistic will be used to measure heterogeneity in the magnitude of pooled estimates [18]. I-squared statistics near 25% indicate low heterogeneity, values near 50% indicate moderate heterogeneity, and those above 75% indicate high heterogeneity [19]. If there is moderate to significant heterogeneity in estimates, potential causes, including clinical stage at cotrimoxazole initiation, study design, and the burden of infectious diseases in the country where studies were conducted may be explored using sensitivity analyses. STATA version 12.0 will be used for all analyses. Quality assessment For the quality assessment, studies will be stratified based on study design (i.e. randomised controlled trial or observational study). Per recommendations from the Cochrane Collaboration, the Collaboration s Risk of bias tool will be used to assess bias in randomised trials [20]. This tool rates studies based on six criteria in four sources of bias. The presence of random sequence generation for allocation into intervention and comparator arms, and attempts to conceal this allocation, will be used to gauge selection bias. Blinding of study participants, personnel, and outcome assessment during the conduct and analysis of the studies will be used to gauge performance and detection bias. Incomplete outcome data, through review of participants excluded from outcome analyses or lost to follow-up, will be
5 used to gauge attrition bias. Selective reporting of outcomes, time-points, subgroups, or analyses, will be used to gauge reporting bias. A criterion for other forms of bias will also be used. Based on these criteria, studies will be scored out of 100%. Per recommendations from the Cochrane Collaboration [20], the Newcastle-Ottawa Quality Assessment Scale will be used to assess bias in observational studies [21]. This scale rates studies based on eight criteria in three sources of bias. Each criterion is worth one point except confounding, which is worth two points. Selection bias will be assessed using four criteria: (1) representativeness of the cohort on cotrimoxazole to the average person on cotrimoxazole in the community in which study participants were drawn, (2) representativeness of the cohort off cotrimoxazole to the cohort on cotrimoxazole, (3) ascertainment of cotrimoxazole use, and (4) demonstration that the outcome was not present at the start of follow up. Adjustment for CD4 count will be used to judge whether appropriate methods were used to address confounding. Measurement bias will be assessed using three criteria: (1) assessment of outcome, (2) adequate follow-up to detect the outcome, and (3) 30% of participants lost to follow up during the study. The quality of evidence will be assessed using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system to guide HIV programme managers and other policy makers on appropriate cotrimoxazole use (Appendix, [22]).
6 Table 1. Search strategy for all databases. Search Search terms number 1 AIDS 2 HIV 3 human immunodeficiency virus 4 1 or 2 or 3 5 cotrimoxazole 6 co-trimoxazole 7 CPT 8 bactrim 9 bactrimel 10 septrin 11 septra 12 septrim 13 trimethoprim-sulfamethoxazole 14 sulfamethoxazole-trimethoprim 15 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or and 15
7 REFERENCES 1. World Health Organization. Global update on HIV treatment 2013: Results, impact and opportunities [cited 23 July 2013]; Available from: 2. United Nations General Assembly. Political Declaration on HIV and AIDS: Intensifying Our Efforts to Eliminate HIV and AIDS [cited 15 November 2012]; Available from: 0_un_a-res _en.pdf 3. Joint United Nations Programme on HIV and AIDS. Global Report: UNAIDS report on the global AIDS epidemic [cited 23 September 2013]; Available from: UNAIDS_Global_Report_2013_en.pdf 4. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIVrelated infections among children, adolescents and adults [cited February]; Available from: 5. Date AA, Vitoria M, Granich R, Banda M, Fox MY, et al. (2010) Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ 88: Harries AD, Zachariah R, Chimzizi R, Salaniponi F, Gausi F, et al. (2011) Operational research in Malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV. BMC Public Health 11: Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. (1996) A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 156: Bucher HC, Griffith L, Guyatt GH, Opravil M. (1997) Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIVinfected patients. J Acquir Immune Defic Syndr Hum Retrovirol 15: Gallant JE, Moore RD, Chaisson RE. (1994) Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 120: Trikalinos TA, Ioannidis JP. (2001) Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis 33: Grimwade K, Swingler. (2003) Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. Cochrane Database Syst Rev CD Suthar AB, Granich R, Mermin J, Van Rie A. (2012) Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and metaanalysis. Bull World Health Organ 90: 128C-38C. 13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e World Health Organization. WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) [cited 25 October 2013]; Available from: SP_implementation_11april2013.pdf.pdf 15. Cooper H, Hedges L. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994.
8 16. D'Agostino RB, Sr., Massaro JM, Sullivan LM. (2003) Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med 22: Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. (2006) Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. Jama 295: Higgins JP, Thompson SG. (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: Higgins JP, Thompson SG, Deeks JJ, Altman DG. (2003) Measuring inconsistency in meta-analyses. Bmj 327: The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. [cited 19 April 2011]; Available from: Wells G, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 23 February 2011]; Available from: Schünemann H, Brozek J, Oxman A, editors. GRADE Handbook: for grading the quality of evidence and the strength of recommendations [cited 29 March 2012]; Available from:
9 APPENDIX For systematic reviews, the GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest. The quality rating across studies has four levels: high, moderate, low, or very low. High quality indicates that further research is very unlikely to change our confidence in the estimate of effect. Moderate quality indicates that further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality indicates that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality indicates that any estimate of effect is very uncertain. By default randomised trials are categorised as high quality and can be downgraded while cohort studies are categorised as low quality and can be upgraded or downgraded. The GRADE Profiler software will be used for performing the GRADE assessment (GRADEprofiler version 3.2.2). There are five factors that can decrease the quality of a body of evidence. The first factor is major limitations in study design or execution that are likely to result in a biased assessment of the effect estimate. This factor will be gauged by assessing the risk of bias across studies. When the proportion of information from studies at high risk of bias is sufficient to affect the interpretation of results, the risk of bias across studies will be high. When most data included in the GRADE review is insufficient to affect the interpretation of results, the risk of bias across studies will be low. When most information included in the GRADE review is from studies at an unclear risk of bias, the risk of bias across studies will be unclear. Low risk of bias will indicate no limitation, an unclear risk of bias will indicate no limitation or serious limitation, and a high risk of bias will indicate serious limitation or very serious limitation. The second factor that can decrease the quality of a body of evidence is indirectness of evidence. Indirectness of evidence refers to bodies of literature that do not correspond to the population, intervention, comparator, and outcome specified in the inclusion criteria. The third factor that can decrease the quality of a body of evidence is inconsistency of study results. This would primarily be when studies yield widely different estimates of effect in terms of heterogeneity or variability in results. The fourth factor that can decrease the quality of a body of evidence is imprecision of results, i.e. when there are few participants, few events, and wide confidence intervals. The fifth and final factor that can decrease the quality of a body of evidence is high probability of publication bias. This would be when investigators fail to publish studies or outcomes on the basis of their results.
10 There are three factors that can increase the quality level of a body of evidence. The first factor is a large magnitude of effect. In the absence of plausible confounders, a large effect (i.e. RR > 2 or RR < 0.5) increases the quality one level while a very large effect (i.e. RR > 5 or RR < 0.2) increases the quality two levels. The second factor is plausible confounding that reduces the effect demonstrated in the included studies. The third factor is the presence of a dose-response gradient.
Problem solving therapy
Introduction People with severe mental illnesses such as schizophrenia may show impairments in problem-solving ability. Remediation interventions such as problem solving skills training can help people
More informationResults. NeuRA Treatments for internalised stigma December 2017
Introduction Internalised stigma occurs within an individual, such that a person s attitude may reinforce a negative self-perception of mental disorders, resulting in reduced sense of selfworth, anticipation
More informationResults. NeuRA Hypnosis June 2016
Introduction may be experienced as an altered state of consciousness or as a state of relaxation. There is no agreed framework for administering hypnosis, but the procedure often involves induction (such
More informationResults. NeuRA Forensic settings April 2016
Introduction Prevalence quantifies the proportion of individuals in a population who have a disease during a specific time period. Many studies have reported a high prevalence of various health problems,
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More informationDistraction techniques
Introduction are a form of coping skills enhancement, taught during cognitive behavioural therapy. These techniques are used to distract and draw attention away from the auditory symptoms of schizophrenia,
More informationSchool of Dentistry. What is a systematic review?
School of Dentistry What is a systematic review? Screen Shot 2012-12-12 at 09.38.42 Where do I find the best evidence? The Literature Information overload 2 million articles published a year 20,000 biomedical
More informationResults. NeuRA Worldwide incidence April 2016
Introduction The incidence of schizophrenia refers to how many new cases there are per population in a specified time period. It is different from prevalence, which refers to how many existing cases there
More informationResults. NeuRA Mindfulness and acceptance therapies August 2018
Introduction involve intentional and non-judgmental focus of one's attention on emotions, thoughts and sensations that are occurring in the present moment. The aim is to open awareness to present experiences,
More informationAnimal-assisted therapy
Introduction Animal-assisted interventions use trained animals to help improve physical, mental and social functions in people with schizophrenia. It is a goal-directed intervention in which an animal
More informationResults. NeuRA Family relationships May 2017
Introduction Familial expressed emotion involving hostility, emotional over-involvement, and critical comments has been associated with increased psychotic relapse in people with schizophrenia, so these
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2018 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationThe QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews
The QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews David Moher 1, Alessandro Liberati 2, Douglas G Altman 3, Jennifer Tetzlaff 1 for the QUOROM Group
More informationAgomelatine versus placebo: A meta-analysis of published and unpublished trials
Agomelatine versus placebo: A meta-analysis of published and unpublished trials (Protocol for a systematic review, Ulm, January 17, 2011) Markus Kösters, Andrea Cipriani, Giuseppe Guaiana, Thomas Becker
More informationNeuRA Obsessive-compulsive disorders October 2017
Introduction (OCDs) involve persistent and intrusive thoughts (obsessions) and repetitive actions (compulsions). The DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) defines
More informationCopyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD
GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD ASSISTANT PROFESSOR DEPARTMENT OF CLINICAL EPIDEMIOLOGY AND BIOSTATISTICS, MCMASTER UNIVERSITY Nancy Santesso,
More informationReporting guidelines
Reporting guidelines Diaa E.E. Rizk Editor, International Urogynecology Journal rizk.diaa@gmail.com IUGA 2015 Nice Workshop #7 How to publish and review 9 June 2015 Aim of reporting guidelines Standardize
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with first
More informationResults. NeuRA Maternal infections April 2016
Introduction Maternal infection during pregnancy with Toxoplasma gondii, rubella, cytomegalovirus (CMV), herpes simplex virus (HSV) and other microbes have been known to be associated with brain and behavioural
More informationResults. NeuRA Motor dysfunction April 2016
Introduction Subtle deviations in various developmental trajectories during childhood and adolescence may foreshadow the later development of schizophrenia. Studies exploring these deviations (antecedents)
More informationResults. NeuRA Treatments for dual diagnosis August 2016
Introduction Many treatments have been targeted to improving symptom severity for people suffering schizophrenia in combination with substance use problems. Studies of dual diagnosis often investigate
More informationCochrane Pregnancy and Childbirth Group Methodological Guidelines
Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews
More informationTranscranial Direct-Current Stimulation
Introduction (tdcs) is a non-invasive form of brain stimulation similar to transcranial magnetic stimulation, but instead of using magnets, it uses a lowintensity, constant current applied through scalp
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationHow to Conduct a Meta-Analysis
How to Conduct a Meta-Analysis Faculty Development and Diversity Seminar ludovic@bu.edu Dec 11th, 2017 Periodontal disease treatment and preterm birth We conducted a metaanalysis of randomized controlled
More informationSystematic Review of RCTs of Haemophilus influenzae Type b Conjugate Vaccines: Efficacy and immunogenicity
Supplementary text 1 Systematic Review of RCTs of Haemophilus influenzae Type b Conjugate Vaccines: Efficacy and immunogenicity Review protocol Pippa Scott, Shelagh Redmond, Nicola Low and Matthias Egger
More informationWhat is indirect comparison?
...? series New title Statistics Supported by sanofi-aventis What is indirect comparison? Fujian Song BMed MMed PhD Reader in Research Synthesis, Faculty of Health, University of East Anglia Indirect comparison
More informationCEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews
CEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews Since September 2013, the CEU has been responsible for pre-publication screening of new intervention
More informationLearning from Systematic Review and Meta analysis
Learning from Systematic Review and Meta analysis Efficacy and Safety of Antiscabietic Agents: A Systematic Review and Network Meta analysis of Randomized Controlled Trials KUNLAWAT THADANIPON, MD 4 TH
More informationNeuRA Sleep disturbance April 2016
Introduction People with schizophrenia may show disturbances in the amount, or the quality of sleep they generally receive. Typically sleep follows a characteristic pattern of four stages, where stage
More informationMeta-analyses: analyses:
Meta-analyses: analyses: how do they help, and when can they not? Lee Hooper Senior Lecturer in research synthesis & nutrition l.hooper@uea.ac.uk 01603 591268 Aims Systematic Reviews Discuss the scientific
More informationGRADE tables to assist guideline development and recommendations. Plain Language Summary of Results
Seasonal Malaria Chemoprevention (formally known as Intermittent Preventive Treatment in children) for preventing malaria morbidity in children aged less than 5 years living in areas of marked seasonal
More informationChoice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias
Technical appendix Choice of axis, tests for funnel plot asymmetry, and methods to adjust for publication bias Choice of axis in funnel plots Funnel plots were first used in educational research and psychology,
More informationPapers. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses.
Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses Fujian Song, Douglas G Altman, Anne-Marie Glenny, Jonathan J Deeks Abstract
More informationControlled Trials. Spyros Kitsiou, PhD
Assessing Risk of Bias in Randomized Controlled Trials Spyros Kitsiou, PhD Assistant Professor Department of Biomedical and Health Information Sciences College of Applied Health Sciences University of
More informationResults. NeuRA Essential fatty acids August 2016
Introduction Alternative treatments are investigated as a possible replacement for antipsychotic medication, which can be associated with severe side effects. Alternative therapies may have less debilitating
More informationAnnex 2. GRADE glossary and summary of evidence tables
WHO/HTM/TB/2011.6b. GRADE glossary and summary of evidence tables GRADE glossary Absolute effect The absolute measure of intervention effects is the difference between the baseline risk of an outcome (for
More informationWorkshop: Cochrane Rehabilitation 05th May Trusted evidence. Informed decisions. Better health.
Workshop: Cochrane Rehabilitation 05th May 2018 Trusted evidence. Informed decisions. Better health. Disclosure I have no conflicts of interest with anything in this presentation How to read a systematic
More informationNeuRA Decision making April 2016
Introduction requires an individual to use their knowledge and experience of a context in order to choose a course of action 1. A person s ability to autonomously make decisions is referred to as their
More informationEvaluating the results of a Systematic Review/Meta- Analysis
Open Access Publication Evaluating the results of a Systematic Review/Meta- Analysis by Michael Turlik, DPM 1 The Foot and Ankle Online Journal 2 (7): 5 This is the second of two articles discussing the
More informationMethod. NeuRA Biofeedback May 2016
Introduction is a technique in which information about the person s body is fed back to the person so that they may be trained to alter the body s conditions. Physical therapists use biofeedback to help
More informationJOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN
JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN WHO, UNAIDS and UNICEF, guided by recent evidence, have agreed to modify as an interim
More informationNeuRA Schizophrenia diagnosis May 2017
Introduction Diagnostic scales are widely used within clinical practice and research settings to ensure consistency of illness ratings. These scales have been extensively validated and provide a set of
More informationResults. NeuRA Herbal medicines August 2016
Introduction have been suggested as a potential alternative treatment which may positively contribute to the treatment of schizophrenia. Herbal therapies can include traditional Chinese medicines and Indian
More informationPROTOCOL. Francesco Brigo, Luigi Giuseppe Bongiovanni
COMMON REFERENCE-BASED INDIRECT COMPARISON META-ANALYSIS OF INTRAVENOUS VALPROATE VERSUS INTRAVENOUS PHENOBARBITONE IN GENERALIZED CONVULSIVE STATUS EPILEPTICUS PROTOCOL Francesco Brigo, Luigi Giuseppe
More information1. PICO question. Interventions Reference standard or comparators Outcomes. Study design Other
Title: Strategies for optimizing HIV monitoring among adults, children and pregnant women living with HIV receiving antiretroviral therapy: a systematic review Contents 1. PICO question... 1 2. Search
More informationA protocol for a systematic review on the impact of unpublished studies and studies published in the gray literature in meta-analyses
Systematic Reviews This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. A protocol for a systematic
More informationSystematic Reviews. Simon Gates 8 March 2007
Systematic Reviews Simon Gates 8 March 2007 Contents Reviewing of research Why we need reviews Traditional narrative reviews Systematic reviews Components of systematic reviews Conclusions Key reference
More informationScaling up priority HIV/AIDS interventions in the health sector
TOWARDS UNIVERSAL ACCESS? Scaling up priority HIV/AIDS interventions in the health sector Yves Souteyrand, WHO October 2011 Towards universal access targets UN General Assembly High level Meeting June
More informationIntroduction to systematic reviews/metaanalysis
Introduction to systematic reviews/metaanalysis Hania Szajewska The Medical University of Warsaw Department of Paediatrics hania@ipgate.pl Do I needknowledgeon systematicreviews? Bastian H, Glasziou P,
More informationGoal of this chapter. 6.1 Introduction Good practices for linkage to care General care for people living with HIV 84
Clinical guidelines across THE CONTINuUM OF CARE: LINKING PEOPLE DIAGNOSEd WiTH hiv infection to hiv care and treatment 06 6.1 Introduction 84 6.2 Good practices for linkage to care 84 6.3 General care
More informationMethod. NeuRA Cholinesterase inhibitors August 2016
Introduction A supplementary, or adjunctive, treatment is administered in conjunction with a patient s ongoing antipsychotic therapy. (ChEI), or anticholinesterase, have been proposed as an additional
More informationRobert M. Jacobson, M.D. Department of Pediatric and Adolescent Medicine Mayo Clinic, Rochester, Minnesota
How to Conduct a Systematic Review: A Workshop 24 th Annual Primary Care Research Methods & Statistics Conference, San Antonio, Texas Saturday, December 3, 2011 Robert M. Jacobson, M.D. Department of Pediatric
More informationProgram to control HIV/AIDS
90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,
More informationEssential Skills for Evidence-based Practice Understanding and Using Systematic Reviews
J Nurs Sci Vol.28 No.4 Oct - Dec 2010 Essential Skills for Evidence-based Practice Understanding and Using Systematic Reviews Jeanne Grace Corresponding author: J Grace E-mail: Jeanne_Grace@urmc.rochester.edu
More informationEvidence based urology in practice: heterogeneity in a systematic review meta-analysis. Health Services Research Unit, University of Aberdeen, UK
Version 6, 12/10/2009 Evidence based urology in practice: heterogeneity in a systematic review meta-analysis Mari Imamura 1, Jonathan Cook 2, Sara MacLennan 1, James N Dow 1 and Philipp Dahm 3 for the
More informationIs implant placement a risk in patients with increased susceptibility to periodontitis?
C L I N I C A L Is implant placement a risk in patients with increased susceptibility to periodontitis? Johan Hartshorne 1 A critical appraisal of a systematic review: Chrcanovic BR, Albrektsson T, Wennerberg
More informationCONSORT 2010 checklist of information to include when reporting a randomised trial*
CONSORT 2010 checklist of information to include when reporting a randomised trial* Section/Topic Title and abstract Introduction Background and objectives Item No Checklist item 1a Identification as a
More informationDeterminants of quality: Factors that lower or increase the quality of evidence
Determinants of quality: Factors that lower or increase the quality of evidence GRADE Workshop CBO, NHG and Dutch Cochrane Centre CBO, April 17th, 2013 Outline The GRADE approach: step by step Factors
More informationNeuRA Schizophrenia diagnosis June 2017
Introduction Diagnostic scales are widely used within clinical practice and research settings to ensure consistency of illness ratings. These scales have been extensively validated and provide a set of
More informationACR OA Guideline Development Process Knee and Hip
ACR OA Guideline Development Process Knee and Hip 1. Literature searching frame work Literature searches were developed based on the scenarios. A comprehensive search strategy was used to guide the process
More information18/11/2013. An Introduction to Meta-analysis. In this session: What is meta-analysis? Some Background Clinical Trials. What questions are addressed?
In this session: What is meta-analysis? An Introduction to Meta-analysis Geoff Der Unit Statistician MRC/CSO Social and Public Health Sciences Unit, University of Glasgow When is it appropriate to use?
More informationSystematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)
Systematic Review & Meta-analysisanalysis Ammarin Thakkinstian, Ph.D. Section for Clinical Epidemiology and Biostatistics Faculty of Medicine, Ramathibodi Hospital Tel: 02-201-1269, 02-201-1762 Fax: 02-2011284
More informationCapture-recapture method for assessing publication bias
Received: 30.9.2009 Accepted: 19.1.2010 Original Article Capture-recapture method for assessing publication bias Jalal Poorolajal* a, Ali Akbar Haghdoost b, Mahmood Mahmoodi a, Reza Majdzadeh a, Siavosh
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Prophylactic cranial irradiation in patients with non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled
More informationImproving UNAIDS paediatric and adolescent estimates
Improving UNAIDS paediatric and adolescent estimates BACKGROUND This document provides paediatric HIV programme managers with an overview of how paediatric and adolescent estimates are produced, what the
More informationStructural barriers to highly active antiretroviral therapy (HAART) adherence: a systematic review protocol
Structural barriers to highly active antiretroviral therapy (HAART) adherence: a systematic review protocol Garumma Tolu Feyissa MPH 1,5 Aderajew Nigussie MPH 2,5 Tariku Dejene Demissie MSc 3,5 Mirkuzie
More informationUCSF/WHO Systematic Review
UCSF/WHO Systematic Review Monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure among adults and adolescents living with HIV in low-resource
More informationAssessing Tuberculosis Case Fatality Ratio: A Meta- Analysis
: A Meta- Analysis Masja Straetemans 1,2 *, Philippe Glaziou 3, Ana L. Bierrenbach 3, Charalambos Sismanidis 3, Marieke J. van der Werf 1,2 1 Unit Knowledge, Research and Policy, KNCV Tuberculosis Foundation,
More informationParticipant views and experiences of participating in HIV research in sub-saharan Africa: a qualitative systematic review protocol
Participant views and experiences of participating in HIV research in sub-saharan Africa: a qualitative systematic review protocol Sylvia Nalubega, RN, BSc, MSc 1 Catrin Evans, RN, BSc, MA, PhD 1 1. The
More informationAntiretroviral resistance testing in HIV-positive people (Review)
Cochrane Database of Systematic Reviews Antiretroviral resistance testing in HIV-positive people (Review) Aves T, Tambe J, Siemieniuk RAC, Mbuagbaw L Aves T, Tambe J, Siemieniuk RAC, Mbuagbaw L. Antiretroviral
More informationNeuRA Schizophrenia diagnosis October 2017
Introduction Diagnostic scales are widely used within clinical practice and research settings to ensure consistency of illness ratings. These scales have been extensively validated and provide a set of
More informationARCHE Risk of Bias (ROB) Guidelines
Types of Biases and ROB Domains ARCHE Risk of Bias (ROB) Guidelines Bias Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias Other Bias ROB Domain Sequence generation Allocation
More informationZhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou 1,2,3 Author affiliation:
Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: AMeta-analysis of Prospective Studies Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou
More informationCochrane Breast Cancer Group
Cochrane Breast Cancer Group Version and date: V3.2, September 2013 Intervention Cochrane Protocol checklist for authors This checklist is designed to help you (the authors) complete your Cochrane Protocol.
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Closed reduction methods for acute anterior shoulder dislocation [Cochrane Protocol] Kanthan Theivendran, Raj Thakrar, Subodh Deshmukh,
More informationScaling-up antiretroviral therapy in Malawi
Andreas Jahn et al. Scale-up of antiretroviral therapy in Malawi This online first version has been peer-reviewed, accepted and edited, but not formatted and finalized with corrections from authors and
More informationObjective: Specific Aims:
Title: Retention to Care of HIV pregnant females in Kumasi, Ghana Brown Faculty: Aadia Rana, MD. Assistant Professor of Medicine in Division of Infectious Diseases, Awewura Kwara, Assistant Professor of
More informationReviewer No. 1 checklist for application of: inclusion of Nifurtimox + eflornithine in the WHO Essential Medicines List
Reviewer No. 1 checklist for application of: inclusion of Nifurtimox + eflornithine in the WHO Essential Medicines List (1) Have all important studies that you are aware of been included? No additional
More informationGarbage in - garbage out? Impact of poor reporting on the development of systematic reviews
Garbage in - garbage out? Impact of poor reporting on the development of systematic reviews ACT now: EQUATOR Scientific Symposium Freiburg, 11 October 2012 Erik von Elm, MD MSc FMH Cochrane Switzerland
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Drug-eluting balloon angioplasty versus non-stenting balloon angioplasty for peripheral arterial disease of the lower limbs [Cochrane Protocol]
More informationAntiretroviral therapy for adults and adolescents KEY MESSAGES. HIV/AIDS Department BACKGROUND
KEY MESSAGES New WHO Recommendations: Antiretroviral therapy for adults and adolescents The World Health Organization (WHO) is revising its guidelines on antiretroviral therapy (ART) for adults and adolescents.
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationSystematic reviews and meta-analyses
Systematic reviews and meta-analyses Oulu 8.4.2015 Jouko Miettunen, professor Center for Life Course Epidemiology and Systems Medicine University of Oulu jouko.miettunen@oulu.fi Contents Background Literature
More informationAIDS at 30 Epidemiology and Clinical Epidemiology and Management MID 37
AIDS at 30 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Adults and children
More informationMeta-Analyses: Considerations for Probiotics & Prebiotics Studies
Meta-Analyses: Considerations for Probiotics & Prebiotics Studies Daniel J. Tancredi, PhD Associate Professor in Residence Department of Pediatrics UC Davis School of Medicine Objectives Provide an overview
More informationCochrane Bone, Joint & Muscle Trauma Group How To Write A Protocol
A p r i l 2 0 0 8 Cochrane Bone, Joint & Muscle Trauma Group How To Write A Protocol This booklet was originally produced by the Cochrane Renal Group to make the whole process of preparing a protocol as
More informationAIDS at 25. Epidemiology and Clinical Management MID 37
AIDS at 25 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Regional HIV and
More informationResearch Article Challenges in Assessing Outcomes among Infants of Pregnant HIV-Positive Women Receiving ART in Uganda
Hindawi AIDS Research and Treatment Volume 2017, Article ID 3202737, 4 pages https://doi.org/10.1155/2017/3202737 Research Article Challenges in Assessing Outcomes among Infants of Pregnant HIV-Positive
More informationFixed Effect Combining
Meta-Analysis Workshop (part 2) Michael LaValley December 12 th 2014 Villanova University Fixed Effect Combining Each study i provides an effect size estimate d i of the population value For the inverse
More informationDownloaded from:
Arnup, SJ; Forbes, AB; Kahan, BC; Morgan, KE; McKenzie, JE (2016) The quality of reporting in cluster randomised crossover trials: proposal for reporting items and an assessment of reporting quality. Trials,
More information1. Draft checklist for judging on quality of animal studies (Van der Worp et al., 2010)
Appendix C Quality appraisal tools (QATs) 1. Draft checklist for judging on quality of animal studies (Van der Worp et al., 2010) 2. NICE Checklist for qualitative studies (2012) 3. The Critical Appraisal
More informationMeta Analysis. David R Urbach MD MSc Outcomes Research Course December 4, 2014
Meta Analysis David R Urbach MD MSc Outcomes Research Course December 4, 2014 Overview Definitions Identifying studies Appraising studies Quantitative synthesis Presentation of results Examining heterogeneity
More informationWeb appendix (published as supplied by the authors)
Web appendix (published as supplied by the authors) In this appendix we provide motivation and considerations for assessing the risk of bias for each of the items included in the Cochrane Collaboration
More informationCotrimoxazole Prophylaxis in HIV-Infected Pregnant Women and their Infants: Associations with Parasitemia, Common Illnesses and Birth Outcomes
Cotrimoxazole Prophylaxis in HIV-Infected Pregnant Women and their Infants: Associations with Parasitemia, Common Illnesses and Birth Outcomes Anna Elizabeth Dow A dissertation submitted to the faculty
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationDecision aids for people considering taking part in clinical trials(review)
Cochrane Database of Systematic Reviews Decision aids for people considering taking part in clinical trials(review) GilliesK,CottonSC,BrehautJC,PolitiMC,SkeaZ GilliesK,CottonSC,BrehautJC,PolitiMC,SkeaZ.
More informationWho should lead a trauma team: Surgeon or nonsurgeon? A systematic review and meta-analysis
Hajibandeh Sh & Hajibandeh Sh Injury & Violence 107 J Inj Violence Res. 2017 Jul; 9(2): 107-116. doi: 10.5249/ jivr.v9i2.874 Review Article Who should lead a trauma team: Surgeon or nonsurgeon? A systematic
More informationEvidence- and Value-based Solutions for Health Care Clinical Improvement Consults, Content Development, Training & Seminars, Tools
Definition Key Points Key Problems Bias Choice Lack of Control Chance Observational Study Defined Epidemiological study in which observations are made, but investigators do not control the exposure or
More information